Cardiac‐peripheral transvenous gradients of microRNA expression in systolic heart failure patients

Abstract

Aims The aims of the study are to assess the levels of coronary sinus (CS) miRNAs of systolic heart failure (HF) patients in samples obtained during cardiac resynchronization therapy (CRT) device implantation and compare them to the peripheral systemic venous miRNA expression. Methods and ResultsThe cardiac specific miRNA levels were assessed in 60 patients, 39 HF patients with reduced ejection fraction and 21 control patients. The levels of four cardiac specified miRNAs (miR-21-5p, miR-92b-3p, miR-125b-5p, and miR-133a-3p) were compared between the peripheral samples of HF and controls and between peripheral venous in CS in the HF groups. Compared with controls, HF patients had higher peripheral serum venous levels of miR-125b-5p and miR-133-3p. In the HF group, the levels of expression were higher for miR-125b-5p and lower for miR-92, and miR-21-5p in the CS, compared with the peripheral venous circulation. Conclusions The differences in miRNA expressions in CS compared with those in the periphery suggest that changes that may occur at the levels of the myocardial tissue in HF may be more relevant to our understanding of the biological linkage between miRNA expression and HF, than the traditional analysis of systemic serum miRNA expression. declare that they have no conflict of interest.Cardiac-peripheral transvenous gradients of microRNA expression in systolic heart failure patients 841 ESC Heart Failure 2020; 7: 835-843

Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy

“…No significant associations were found between miR-125b-5p and other clinical biomarkers. Higher circulating levels of miR-125b have been described in HF patients as compared with no-HF patients [ 22 , 29 , 42 ]. Interestingly, recent data suggest that miR-125b might be secreted by cardiac tissue [ 22 ].…”

“…Among dysregulated miRNAs in CVD, miR-499 and miR-125b-5p have been closely involved in HF; both have been described as highly expressed cardiac miRNAs, which are released under stressful conditions [ 10 , 21 , 22 ] as well as good circulating biomarkers in HF [ 22 , 23 ].…”

The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene

“…miR-92b-3p, along with miR-133a-3p, is one of the cardiac specific miRNAs involved in heart failure (i.e., cardiomyocyte apoptosis, hypertrophy, and inflammation) and was reduced in the coronary sinus of patients with heart failure [ 58 ]. In particular, miR-92b-3p was observed to be decreased in mouse hypertrophic cardiomyocytes upon angiotensin II antagonist treatment and its overexpression can attenuate the hypertrophic phenotype by downregulating the hypertrophy related genes [ 58 – 60 ]. Mdx mice show a mild cardiomyopathy and, according to the literature, we found that at T16, miR-92b-3p in naive mdx plasma was downregulated compared to naive wt mice (FC = − 0.896, not significant).…”

The Integrative Analysis of Competitive Endogenous RNA Regulatory Networks in Coronary Artery Disease

“…MiR-92b-3p-DKK3 and miR-25-3p-TMEM184B were also identified in our study. Compared with the peripheral venous circulation, the level of expression was lower for miR-92b-3p in the coronary sinus of patients with heart failure ( 51 ). The expression level of miR-92b-3p was lower under the hypoxic condition, and it can inhibit proliferation and cell cycle progression in pulmonary arterial hypertension ( 52 ).…”